SONOSCAPE(SZ:300633) Sou Hu Cai Jing·2026-02-12 13:19Core Viewpoint - The company, Kaili Medical (300633), has shown mixed financial performance with a slight increase in revenue but a significant decline in net profit for the first three quarters of 2025 [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue reached 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company reported a single-quarter revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Market Activity - As of February 12, 2026, the stock closed at 26.88 yuan, with a slight increase of 0.3% [1]. - The trading volume was 26,000 hands, with a total transaction amount of 69.61 million yuan [1]. - On February 12, the net inflow of main funds was 1.83 million yuan, accounting for 2.63% of the total transaction amount [1]. - Retail investors had a net inflow of 3.88 million yuan, representing 5.58% of the total transaction amount [1]. - Institutional ratings over the last 90 days include 3 buy ratings and 1 hold rating [3].